Inactive Instrument

Sensidose AB Stock

Equities

SENSI

SE0017232671

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Chart Sensidose AB

Duration

Period

Style

Latest news about Sensidose AB

Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB.	23-05-24	CI
EQL Pharma AB cancelled the acquisition of all the remaining stake in Sensidose AB.	23-05-16	CI
Sensidose AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Sweden’s EQL Pharma Increases Bid for Sensidose	23-04-24	MT
Navamedic Raises Takeover Offer for Sensidose, Agrees to Buy 57% Stake	23-04-24	MT
EQL Pharma Launches SEK91 Million Takeover Bid for Sensidose	23-04-20	MT
EQL Pharma AB made an offer to acquire all the remaining stake in to acquire Sensidose AB for SEK 91.7 million.	23-04-19	CI
Navamedic ASA (OB:NAVA) made an offer to acquire Sensidose AB for SEK 96 million.	23-03-28	CI
Sensidose AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Sensidose AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Certain Shares of Sensidose AB are subject to a Lock-Up Agreement Ending on 9-FEB-2023.	23-02-08	CI
Sensidose AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Sensidose Starts Trading on Sweden's Spotlight Stock Market	22-05-12	MT
Sensidose AB has completed an IPO in the amount of SEK 24.2355 million.	22-05-09	CI
Sensidose AB has filed an IPO in the amount of SEK 24.2355 million.	22-04-11	CI

Press releases Sensidose AB

Updated recommendation by the nomination committee of Navamedic ASA	23-05-31	AQ
Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag	23-05-26	AQ
Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer	23-05-26	AQ
EQL Pharma AB publishes the final outcome in public takeover offer. As a result of the shareholder dynamics and other circumstances the Board also announces its intention to sell its holdings.	23-05-17	AQ
Navamedic ASA Q1 2023: Another strong quarter	23-05-11	AQ

More press releases

Managers and Directors - Sensidose AB

Managers	Title	Age	Since
Jack Spira CEO	Chief Executive Officer	71	-
Philip Slatis COO	Chief Operating Officer	-	21-12-31
Per Holm CTO	Chief Tech/Sci/R&D Officer	-	14-12-31

Members of the board	Title	Age	Since
Jack Spira CEO	Chief Executive Officer	71	-
Jostein Davidsen BRD	Director/Board Member	65	-
Lars Hjarrand BRD	Director/Board Member	51	-

Company Profile

Sector

-

More about the company

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW